Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Evanston, IL
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
New Orleans, LA
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Battle Creek, MI
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Southfield, MI
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Southfield, MI
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Edina, MN
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Edina, MN
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Rochester, NY
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Columbus, OH
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Anderson, SC
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Anderson, SC
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Charleston, SC
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Greer, SC
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Corpus Christi, TX
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Houston, TX
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Tomball, TX
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Tomball, TX
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Orem, UT
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Orem, UT
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Manassas, VA
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Manassas, VA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Richmond, VA
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Overland Park, KA
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  10/7/2015
mi
from
Antwerpen,
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 10/7/2015
mi
from
Antwerpen,
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Terence Hart, MD
mi
from
Muscle Shoals, AL
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Terence Hart, MD
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Central Phoenix Medical Clinic
mi
from
Phoenix, AZ
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Central Phoenix Medical Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Pacific Oaks Medical Group
mi
from
Beverly Hills, CA
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Pacific Oaks Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
National Research Institute - Wilshire
mi
from
Los Angeles, CA
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
National Research Institute - Wilshire
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
National Research Institute - East 118
mi
from
Los Angeles, CA
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
National Research Institute - East 118
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Research Across America - Santa Ana
mi
from
Santa Ana, CA
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Research Across America - Santa Ana
mi
from
Santa Ana, CA
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Encompass Clinical Research
mi
from
Spring Valley, CA
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Encompass Clinical Research
mi
from
Spring Valley, CA
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Colorado Springs Health Partners, Pc
mi
from
Colorado Springs, CO
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Colorado Springs Health Partners, Pc
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Clinical Research of South Florida
mi
from
Coral Gables, FL
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Clinical Research of South Florida
mi
from
Coral Gables, FL
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Jacksonville Impotence Treatment Center
mi
from
Jacksonville, FL
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Jacksonville Impotence Treatment Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Compass Research East, LLC
mi
from
Oviedo, FL
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Compass Research East, LLC
mi
from
Oviedo, FL
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Progressive Medical Research
mi
from
Port Orange, FL
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Progressive Medical Research
mi
from
Port Orange, FL
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Meridien Research
mi
from
St. Petersburg, FL
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Meridien Research
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Meridien Research- Tampa
mi
from
Tampa, FL
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Meridien Research- Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Evanston Premier Healthcare Research LLC
mi
from
Evanston, IL
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Evanston Premier Healthcare Research LLC
mi
from
Evanston, IL
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Medisphere Medical Research Center
mi
from
Evansville, IN
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Medisphere Medical Research Center
mi
from
Evansville, IN
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Heartland Research Assoc., LLC
mi
from
Newton, KA
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Heartland Research Assoc., LLC
mi
from
Newton, KA
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
mi
from
Louisville, KY
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
mi
from
Louisville, KY
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Troy Internal Medicine, PC
mi
from
Troy, MI
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Troy Internal Medicine, PC
mi
from
Troy, MI
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Radiant Research - Edina
mi
from
Edina, MN
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Radiant Research - Edina
mi
from
Edina, MN
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Mercury Street Medical
mi
from
Butte, MT
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Mercury Street Medical
mi
from
Butte, MT
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
Peters Medical Research
mi
from
HIgh Point, NC
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
Peters Medical Research
mi
from
HIgh Point, NC
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
PMG Research of Raleigh, LLC
mi
from
Raleigh, NC
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
PMG Research of Raleigh, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  10/7/2015
PMG Research of Wilmington
mi
from
Wilmington, NC
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 10/7/2015
PMG Research of Wilmington
mi
from
Wilmington, NC
Click here to add this to my saved trials